A RANDOMIZED PHASE II TRIAL OF TRIPLET THERAPY (A PD-L1 INHIBITOR DURVALUMAB (MEDI4736) IN COMBINATION WITH OLAPARIB AND CEDIRANIB) COMPARED TO OLAPARIB AND CEDIRANIB OR DURVALUMAB (MEDI4736) AND CEDIRANIB OR STANDARD OF CARE CHEMOTHERAPY IN WOMEN WITH PLATINUM-RESISTANT RECURRENT EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL OR FALLOPIAN CANCER WHO HAVE RECEIVED PRIOR BEVACIZUMAB

Date Added
May 5th, 2022
PRO Number
Pro00120435
Researcher
Whitney Graybill

List of Studies


Keywords
Cancer/Gynecological
Summary

This study is for women with recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer that is resistant to platinum-based chemotherapy and have had prior therapy with bevacizumab.The purpose of the study is to see if the combinations of durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) and cediranib, or olaparib and cediranib keep patients disease free longer than the usual approach.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
(843) 792-9321
hcc-clinical-trials@musc.edu

A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Date Added
November 23rd, 2021
PRO Number
Pro00113024
Researcher
Whitney Graybill

List of Studies


Keywords
Cancer, Cancer/Gynecological, Drug Studies, Women's Health
Summary

This study is for subjects that have platinum-resistant recurrent ovarian cancer. The study is testing an "investigational" study drug called AVB-S6-500. The primary purpose of this study is to evaluate the safety and efficacy of AVB-S6-500 combined with PAC in subjects with platinum-resistant, recurrent ovarian cancer. The subjects may remain in the study for up to 24-months. The subjects will be seen at MUSC every 1 to 2 weeks while receiving study treatment and given the study drug by infusion (IV).

Institution
MUSC
Recruitment Contact
HCC Clinical Trails Office
843-792-9321
hcc-clinical-trials@musc.edu

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Date Added
October 23rd, 2019
PRO Number
Pro00093541
Researcher
Whitney Graybill

List of Studies


Keywords
Cancer/Gynecological
Summary

This study is for women with endometrial cancer. The purpose is to find out if adding a new immunotherapy drug to the usual combination of chemotherapy drugs can lower the chance of your endometrial cancer growing or spreading.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

Date Added
April 30th, 2014
PRO Number
Pro00034096
Researcher
Whitney Graybill

List of Studies


Keywords
Cancer/Gynecological, Women's Health
Summary

This study is for adult women who have advanced or recurrent endometrial (uterine) cancer. The purpose is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating uterine cancer.

Institution
MUSC
Recruitment Contact
Sarah Booker
843-792-9190
bookers@musc.edu



-- OR --